04:43 AM EDT, 10/17/2025 (MT Newswires) -- Revolution Medicines ( RVMD ) said late Thursday that the US Food and Drug Administration granted a non-transferrable voucher for daraxonrasib, a multi-selective inhibitor with the potential to help address various types of cancers.

The voucher was granted under an FDA pilot program designed to accelerate the development and review of certain drugs and biological products aligned with US national health priorities, the company said.

Daraxonrasib got the FDA's breakthrough therapy designation earlier this year.

Revolution Medicines ( RVMD ) shares were up 5.7% in recent premarket activity Friday.